Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label sibeprenlimab in IgA nephropathy
2021-005526-17Phase 3Active
- Sponsor
- Otsuka Holdings
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sibeprenlimab in IgA nephropathy (IgAN), sponsored by Otsuka Holdings. Primary endpoint: Safety and tolerability. Started Dec 2022; status: active.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2021-005526-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005526-17.